期刊文献+

复发性结节病12例临床分析 被引量:5

The clinical analysis of recurrent sarcoidosis in 12 patients.
原文传递
导出
摘要 目的探讨结节病复发的主要临床特点。方法将结节病复发定义为:结节病的临床和影像改变自发或经治疗完全缓解后,又出现结节病活动的证据并经影像学或病理证实。2004年至2008年在我院就诊的符合上述标准的结节病复发患者共12例,对上述患者的临床资料进行总结分析。结果12例中11例为女性,复发时间在缓解后4—38个月。12例结节病复发患者中10例在初治时接受了口服激素治疗,复发大多发生在激素减药过程中或停药早期,病情缓解超过3年复发的2例。3例在复发时有新发脏器受损。结论结节病复发主要发生在激素减量或停药早期,但也有病情稳定数年后复发,结节病患者应接受长期随访,并规范口服激素治疗方案,结节病复发时应进行全面检查,重新评估受累脏器。 Objective To study the main clinical characters of recurrent sarcoidosis. Methods Sarcoidosis recurrence were defined as presenting activity through imaging or histology after having self-relief or treated relief. There were 12 patients who consistent to the standard in all sarcoidosis patients from 2004 to 2008 in our hospital. Results All patients but one were male. The time of recurrent to the remission was from 4 to 38 months. 10 patients recei'~ed oral steroid therapy. Recurrences often occurred in drug reducing or 6 months after drug withdrawal. There were 2 patients with recurrence time greater than 3 years after remission. Three patients presented new organ damages in recurrence. Conclusions The recurrence of sarcoidosis mostly occurred in the course of drug reduction or in the early stage of drug withdrawal and the recurrence time were hardly over 3 years after remission. The sarcoidosis patients must receive long time follow-up and the program of oral steroid therapy must be standardized.
出处 《中国综合临床》 2010年第5期516-518,共3页 Clinical Medicine of China
关键词 结节病 激素 复发 Sarcoidosis Steroid Recurrence
  • 相关文献

参考文献10

  • 1Statement on sarcoidosis.Joint Statement of the American Thoracic Society (ATS),the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Grsnulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee,February 1999[J].Am J Respir Crit Care Med,1999,160(2):736-755.
  • 2Heffner DK.Treatments for pulmonary sarcoidosis[J].Respir Med,2008,102(11):1674.
  • 3秦子敏,何山红,程金华.孤立性肺结节的诊断与治疗[J].中国综合临床,2009,25(4):410-412. 被引量:3
  • 4Ma(n)(a)J,Montero A,Vidal M,et al.Recurrent sarcoidosis:a study of 17 patients with 24 episodes of recurrence[J].Sarcoidosis Vasc Diffuse Lung Dis,2003,20(3):212-221.
  • 5蔡闯,何慕芝,李德荣,李志斌,钟淑卿,钟南山.胸膜肺结节病2例病例报告及文献复习[J].解放军医学杂志,2008,33(11):1362-1365. 被引量:8
  • 6Gottlieb JE,Israel HL,Steiner RM,et al.Outcome in sarcoidosis.The relationship of relapse to corticosteroid therapy[J].Chest,1997,111(3):623-631.
  • 7Coker RK.Management strategies for pulmonary sarcoidosis[J].Ther Clin Risk Manag,2009,5(3):575-584.
  • 8金燕琴.肺结节病18例临床分析[J].中国医药,2008,3(11):699-700. 被引量:4
  • 9Iannuzzi MC,Rybicki BA,Teirstein AS.Sarcoidosis[J].N Engl J Med,2007,357 (21):2153-2165.
  • 10Studdy PR,Bird R.Serum angiotensin converting enzyme in sarcoidosis-its value in present clinical practice[J].Ann Clin Biochem,1989,26(Pt1):13-18.

二级参考文献24

  • 1孙永昌,姚婉贞,沈宁,石雪迎,赵鸣武.结节病胸膜病变分析并文献复习[J].中华结核和呼吸杂志,2006,29(4):243-246. 被引量:28
  • 2Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med, 2007, 357(21):2153.
  • 3Soskel NT, Sharrna OP. Pleural involvement in sarcoidosis. Curr Opin Pulm Med, 2000, 6(5):455.
  • 4Flammang d'Ortho MP, Cadranel J, Milleron BJ, et al. Pleural, alveolar and blood T-lymphocyte subsets in pleuropulmonary sareoidosis. Chest, 1990, 98(3):782.
  • 5Cai C, Li DR, Zeng QS, et al. Prolonged fever, dyspnoea and diffuse pleural thickening in a 20-year-old man. Pleuropulmonary sarcoidosis. Thorax, 2007,62(7): 622.
  • 6Balasubramanian P, Mathew J, Cherian R, et al. Bilateral massive pleural effusion-a rare presentation of sarcoidosis. J Postgrad Med, 2005, 51(4) :335.
  • 7Coker RK. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs, 2007, 67(8):1139.
  • 8Kobashi Y, Matsushima T. Clinical analysis of pulmonary tuberculosis in association with eorticosteroid therapy. Intern Med, 2002, 41 (12) : 1103.
  • 9No authors listed. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med, 1999, 160(2): 736.
  • 10Rebollo AC, Jimenez-Hoyuela JM, Martinez del Valle MD,et al. Lung scintigraphy with technetium 99m depreotide in the assessment of solitary pulmonary nodules [ J ]. Arch Bronconeumol, 2004,40 ( 11 ) :534-536.

共引文献10

同被引文献52

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部